Pages that link to "Q33632141"
Jump to navigation
Jump to search
The following pages link to Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action (Q33632141):
Displaying 50 items.
- An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability (Q24544035) (← links)
- Valproic acid induces monoamine oxidase A via Akt/forkhead box O1 activation (Q24635235) (← links)
- Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain (Q24670430) (← links)
- Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence? (Q24813193) (← links)
- Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia: A Meta-analysis Study (Q26772965) (← links)
- Preclinical antiepileptic actions of selective serotonin reuptake inhibitors--implications for clinical trial design (Q26850811) (← links)
- Physiological maturation and drug responses of human induced pluripotent stem cell-derived cortical neuronal networks in long-term culture (Q27314513) (← links)
- GABA and glutamate in the human brain (Q28216691) (← links)
- (Q28299317) (← links)
- Continuum solvent model studies of the interactions of an anticonvulsant drug with a lipid bilayer. (Q28365695) (← links)
- Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells (Q28366303) (← links)
- Unique behavioral characteristics and microRNA signatures in a drug resistant epilepsy model (Q28538727) (← links)
- Molecular mechanisms of antiseizure drug activity at GABAA receptors (Q28681145) (← links)
- Valproate-induced neurodevelopmental deficits in Xenopus laevis tadpoles. (Q30404772) (← links)
- Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function (Q30438149) (← links)
- HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. (Q30457800) (← links)
- Distinct phenotypes of new transmembrane-domain neuregulin 1 mutant mice and the rescue effects of valproate on the observed schizophrenia-related cognitive deficits (Q30576705) (← links)
- Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage (Q30919683) (← links)
- Long-term valproate treatment increases brain neuropeptide Y expression and decreases seizure expression in a genetic rat model of absence epilepsy (Q31139176) (← links)
- In vivo study of the effect of valpromide and valnoctamide in the pilocarpine rat model of focal epilepsy (Q32015973) (← links)
- Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism (Q33290977) (← links)
- Sodium valproate stimulates potassium and chloride urinary excretion in rats: gender differences (Q33293445) (← links)
- Neuronal peroxisome proliferator-activated receptor gamma signaling: regulation by mood-stabilizer valproate (Q33583998) (← links)
- Hyperammonemia associated with valproic acid concentrations. (Q33608984) (← links)
- B56 regulatory subunit of protein phosphatase 2A mediates valproic acid-induced p300 degradation (Q33695448) (← links)
- Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness (Q33782621) (← links)
- Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience (Q33961525) (← links)
- Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed (Q34082054) (← links)
- Epigenetic GABAergic targets in schizophrenia and bipolar disorder (Q34087810) (← links)
- Anti-tumor mechanisms of valproate: a novel role for an old drug (Q34147644) (← links)
- Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy (Q34150830) (← links)
- Effect of lamotrigine on plasma GABA levels in healthy humans (Q34190168) (← links)
- Treatment of typical absence seizures and related epileptic syndromes (Q34274253) (← links)
- The mechanisms of action of commonly used antiepileptic drugs (Q34305846) (← links)
- Histone deacetylase inhibitors modulates the induction and expression of amphetamine-induced behavioral sensitization partially through an associated learning of the environment in mice (Q34355738) (← links)
- Seizure-induced reduction in PIP3 levels contributes to seizure-activity and is rescued by valproic acid (Q34379505) (← links)
- Anticonvulsants: aspects of their mechanisms of action (Q34558509) (← links)
- Antiepileptic drugs: how they work in headache (Q34570655) (← links)
- Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model. (Q34788228) (← links)
- Anticonvulsants in central pain (Q34974796) (← links)
- Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales (Q35009755) (← links)
- Demographics, assessment and management of pain in the elderly (Q35039129) (← links)
- Topiramate in the treatment of cluster headache (Q35082033) (← links)
- Selection criteria for the clinical use of the newer antiepileptic drugs. (Q35107733) (← links)
- Valproate: past, present, and future. (Q35171196) (← links)
- Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease (Q35385117) (← links)
- Pharmacology of absence epilepsy (Q35559768) (← links)
- Targeted disruption of Kaposi's sarcoma-associated herpesvirus ORF57 in the viral genome is detrimental for the expression of ORF59, K8alpha, and K8.1 and the production of infectious virus (Q35635202) (← links)
- New anticonvulsant medication uses in bipolar disorder (Q35673095) (← links)
- Valproic acid affects membrane trafficking and cell-wall integrity in fission yeast (Q35757628) (← links)